Personalis Announced The Publication Of A New Study In A Journal Of The American Association For Cancer Research, Providing Clinical Evidence That The Company's NeXT Personal, Can Effectively Predict Patient Outcomes Across Various Cancers And Immunotherapy Modalities

The study analyzed 202 patients with stage IV solid tumors—spanning 24 different cancer types—treated with immune checkpoint inhibitors and other immunotherapies. Utilizing a personalized testing approach that tracks up to ~1,800 tumor-specific variants unique to each patient's tumor, the NeXT Personal test achieves ultrasensitive detection of small traces of circulating tumor DNA (ctDNA) from a patient's blood sample.

Key findings published in Clinical Cancer Research include:

• High Sensitivity: The test detected ctDNA in 98% of patients at baseline across all 24 tumor types, demonstrating robust performance even in a diverse set of cancers.
• Early ctDNA Dynamics are Highly Prognostic: Patients who demonstrated decreases in ctDNA levels early in immunotherapy treatment had significantly higher overall survival. Conversely, patients with increasing ctDNA levels early while on immunotherapy had a zero percent overall response rate.
• Durable ctDNA Clearance was a Positive Predictor: Patients who achieved durable molecular clearance (negative ctDNA for at least 180 days) had 100% overall survival (OS) in the study.